Aerovate Therapeutics Earnings Estimate

AVTE Stock  USD 2.58  0.15  6.17%   
The next projected EPS of Aerovate Therapeutics is estimated to be -0.63 with future projections ranging from a low of -0.6525 to a high of -0.6075. Aerovate Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -3.17. Please be aware that the consensus of earnings estimates for Aerovate Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Aerovate Therapeutics is projected to generate -0.63 in earnings per share on the 31st of December 2024. Aerovate Therapeutics earnings estimates show analyst consensus about projected Aerovate Therapeutics EPS (Earning Per Share). It derives the highest and the lowest estimates based on Aerovate Therapeutics' historical volatility. Many public companies, such as Aerovate Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Aerovate Therapeutics' earnings estimates, investors can diagnose different trends across Aerovate Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. The current year's Gross Profit is expected to grow to about (82.1 K)
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.

Aerovate Therapeutics Earnings Estimation Breakdown

The calculation of Aerovate Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Aerovate Therapeutics is estimated to be -0.63 with the future projection ranging from a low of -0.6525 to a high of -0.6075. Please be aware that this consensus of annual earnings estimates for Aerovate Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.56
-0.65
Lowest
Expected EPS
-0.63
-0.61
Highest

Aerovate Therapeutics Earnings Projection Consensus

Suppose the current estimates of Aerovate Therapeutics' value are higher than the current market price of the Aerovate Therapeutics stock. In this case, investors may conclude that Aerovate Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Aerovate Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2024Current EPS (TTM)
387.27%
-0.56
-0.63
-3.17

Aerovate Therapeutics Earnings per Share Projection vs Actual

Actual Earning per Share of Aerovate Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Aerovate Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Aerovate Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Aerovate Therapeutics Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Aerovate Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Aerovate Therapeutics should always be considered in relation to other companies to make a more educated investment decision.

Aerovate Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Aerovate Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-14
2024-09-30-0.17-0.56-0.39229 
2024-08-12
2024-06-30-0.83-0.86-0.03
2024-05-13
2024-03-31-0.76-0.83-0.07
2024-03-25
2023-12-31-0.71-0.74-0.03
2023-11-13
2023-09-30-0.69-0.71-0.02
2023-08-14
2023-06-30-0.7-0.76-0.06
2023-05-15
2023-03-31-0.6-0.67-0.0711 
2023-03-29
2022-12-31-0.62-0.610.01
2022-11-14
2022-09-30-0.5-0.56-0.0612 
2022-08-15
2022-06-30-0.45-0.49-0.04
2022-05-16
2022-03-31-0.28-0.45-0.1760 
2022-03-30
2021-12-31-0.31-0.35-0.0412 
2021-11-15
2021-09-30-0.26-0.260.0
2021-08-16
2021-06-30-0.16-23.8-23.6414775 
2021-06-30
2021-03-310-12.77-12.77
2021-03-31
2020-12-310-3.7007-3.7007
2020-03-31
2019-12-310-1.9147-1.9147

About Aerovate Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Aerovate Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Aerovate Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Aerovate Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-147.1 M-139.7 M
Earnings Yield(0.15)(0.14)
Price Earnings Ratio(7.10)(7.46)
Price Earnings To Growth Ratio(0.19)(0.20)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.17)
Return On Assets
(0.49)
Return On Equity
(0.82)
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.